RxDoctor Payments Data

Theofanis Tsiamtsiouris, MD

Interventional Cardiology · Roslyn, NYNPI 1306897541

Payments from drug & device makers

$3,840in general payments, 2019–2025

Across 155 payments — averaging $24.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Novartis$845
  • Johnson & Johnson$609
  • Abbott$233
  • AstraZeneca$218
  • Novo Nordisk$193
  • plus $728 from 8 others

What the payments were for

  • Food & beverage$3,831100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,840 in reported general payments places this provider in the 25th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$478,232
Medicare patients
1,363
Services billed
4,923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban368$500,801
XareltoRivaroxaban292$392,238
EntrestoSacubitril/Valsartan230$308,238
FarxigaDapagliflozin Propanediol57$72,170
Repatha SureclickEvolocumab81$58,508
AdcircaTadalafil14$50,196
BrilintaTicagrelor44$49,252
MultaqDronedarone Hcl18$41,063
WegovySemaglutide26$33,671
NexlizetBempedoic Acid/Ezetimibe31$20,807
Prasugrel Hcl158$16,312
LivaloPitavastatin Calcium26$16,283
Rosuvastatin Calcium920$14,352
Metoprolol Succinate877$13,710
Praluent PenAlirocumab15$13,012

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$145$500,801368 claims
Johnson & JohnsonXarelto$609$392,238292 claims
NovartisEntresto$845$308,238230 claims
AstraZenecaFarxiga, Brilinta$218$121,422101 claims
Sanofi-aventis U.S. LLCMultaq$25$41,06318 claims
Novo NordiskWegovy$193$33,67126 claims
Esperion Therapeutics, Inc.Nexlizet$58$20,80731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Roslyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →